Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elodie Montaudon

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Breast Cancer Research : BCR|April 2, 2022
Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitorsGuus J J E Heynen, Kamil Lisek, Regina Vogel, et al.
Cancers|October 16, 2024
PLK1 Inhibitor Onvansertib Enhances the Efficacy of Alpelisib in <i>PIK3CA</i>-Mutated HR-Positive Breast Cancer Resistant to Palbociclib and Endocrine Therapy: Preclinical InsightsSreeja Sreekumar, Elodie Montaudon, Davis Klein, et al.
NPJ Breast Cancer|February 17, 2025
Development and validation of a functional ex vivo paclitaxel and eribulin sensitivity assay for breast cancer, the REMIT assayZofia M Komar, Nicole S Verkaik, Ahmed Dahmani, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|July 12, 2021
mTOR Repression in Response to Amino Acid Starvation Promotes ECM Degradation Through MT1-MMP Endocytosis ArrestCecilia Colombero, David Remy, Sandra Antoine-Bally, et al.
Cancers|July 12, 2025
Curcumin Induces Homologous Recombination Deficiency by BRCA2 Degradation in Breast Cancer and Normal CellsZofia M Komar, Marjolijn M Ladan, Nicole S Verkaik, et al.
Cancer Research|November 6, 2025
Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and PatientsLéa Baudre, Gregoire Jouault, Pacôme Prompsy, et al.
Nature Communications|November 2, 2023
Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancerOzge Saatci, Metin Cetin, Meral Uner, et al.
Cancer Research|November 7, 2025
Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and PatientsLéa Baudre, Grégoire Jouault, Pacôme Prompsy, et al.
Cancer Science|March 9, 2026
Targeting PRMTs Creates Vulnerability of DNA Double-Stand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBCCharlène Thiebaut, Sébastien Martinez, Ludivine Pruvost, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2018
Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination TherapyPierre Foidart, Cassandre Yip, Jean Radermacher, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Breast Cancer Research : BCR|April 2, 2022
Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitorsGuus J J E Heynen, Kamil Lisek, Regina Vogel, et al.
Cancers|October 16, 2024
PLK1 Inhibitor Onvansertib Enhances the Efficacy of Alpelisib in <i>PIK3CA</i>-Mutated HR-Positive Breast Cancer Resistant to Palbociclib and Endocrine Therapy: Preclinical InsightsSreeja Sreekumar, Elodie Montaudon, Davis Klein, et al.
NPJ Breast Cancer|February 17, 2025
Development and validation of a functional ex vivo paclitaxel and eribulin sensitivity assay for breast cancer, the REMIT assayZofia M Komar, Nicole S Verkaik, Ahmed Dahmani, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|July 12, 2021
mTOR Repression in Response to Amino Acid Starvation Promotes ECM Degradation Through MT1-MMP Endocytosis ArrestCecilia Colombero, David Remy, Sandra Antoine-Bally, et al.
Cancers|July 12, 2025
Curcumin Induces Homologous Recombination Deficiency by BRCA2 Degradation in Breast Cancer and Normal CellsZofia M Komar, Marjolijn M Ladan, Nicole S Verkaik, et al.
Cancer Research|November 6, 2025
Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and PatientsLéa Baudre, Gregoire Jouault, Pacôme Prompsy, et al.
Nature Communications|November 2, 2023
Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancerOzge Saatci, Metin Cetin, Meral Uner, et al.
Cancer Research|November 7, 2025
Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and PatientsLéa Baudre, Grégoire Jouault, Pacôme Prompsy, et al.
Cancer Science|March 9, 2026
Targeting PRMTs Creates Vulnerability of DNA Double-Stand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBCCharlène Thiebaut, Sébastien Martinez, Ludivine Pruvost, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2018
Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination TherapyPierre Foidart, Cassandre Yip, Jean Radermacher, et al.
Pageof 4